High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis

被引:1
|
作者
Bejko, Dritan [1 ,6 ]
Ernst, Corinna [1 ]
Vergison, Anne [1 ]
Stranges, Saverio [2 ,3 ,4 ,5 ]
Zeegers, Maurice P. [6 ]
Mossong, Joel [1 ]
机构
[1] Hlth Directorate, Hlth Inspectorate, Luxembourg, Luxembourg
[2] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Dept Family Med, London, ON, Canada
[4] Western Univ, Dept Med, London, ON, Canada
[5] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Epidemiol, Maastricht, Netherlands
关键词
Vaccine effectiveness; Natural immunity; COVID-19; Retrospective cohort; Hospital admission; Mortality;
D O I
10.1016/j.vaccine.2024.05.059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. Methods: We linked reported SARS-CoV-2 cases among residents aged >= 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. Results: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1 728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). Conclusions: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
    Andersson, Niklas Worm
    Thiesson, Emilia Myrup
    Baum, Ulrike
    Pihlstrom, Nicklas
    Starrfelt, Jostein
    Faksova, Kristyna
    Poukka, Eero
    Lund, Lars Christian
    Hansen, Christian Holm
    Aakjaer, Mia
    Kjaer, Jesper
    Cohet, Catherine
    Goossens, Mathijs
    Andersen, Morten
    Hallas, Jesper
    Meijerink, Hinta
    Ljung, Rickard
    Hviid, Anders
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 382
  • [22] Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
    Tang, Lin
    Zhang, Yanyang
    Wang, Fuzhen
    Wu, Dan
    Qian, Zhao-Hui
    Zhang, Rui
    Wang, Ai-Bin
    Huang, Chang
    Wang, Haifeng
    Ye, Ying
    Lu, Mingxia
    Wang, Changshuang
    Ma, Ya-Ting
    Pan, Jingjing
    Li, Ya-fei
    Lv, Xiao-Ya
    An, Zhijie
    Rodewald, Lance
    Wang, Xuan-Yi
    Shao, Yi-Ming
    Wu, Zhi-Yin
    Yin, Zundong
    BMJ OPEN, 2022, 12 (11):
  • [23] Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study
    Piernas, Carmen
    Patone, Martina
    Astbury, Nerys M.
    Gao, Min
    Sheikh, Aziz
    Khunti, Kamlesh
    Shankar-Hari, Manu
    Dixon, Sharon
    Coupland, Carol
    Aveyard, Paul
    Hippisley-Cox, Julia
    Jebb, Susan A.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (08): : 571 - 580
  • [24] Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks
    Albreiki, Mohammed
    Mousa, Mira
    Azman, Syafiq Kamarul
    Vurivi, Hema
    Alhalwachi, Zainab
    Alshehhi, Fatima
    AlShamsi, Safiya
    Marzouqi, Nada Al
    Alawadi, Tayba
    Alrand, Hussain
    Oulhaj, Abderrahim
    Fikri, Asma
    Alsafar, Habiba
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave
    La, Yeon Ju
    Oh, Won Sup
    Kim, Changhyup
    Lim, Myoung-nam
    Jeon, Yong Duk
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [26] Effect of inactivated vaccine boosters against severe and critical COVID-19 during the Omicron BA.5 wave: A retrospective analysis of hospitalized patients in China
    Gan, Jiadi
    Zhang, Huohuo
    Wu, Jiaxuan
    Liu, Yi
    Liu, Pingping
    Cheng, Ruixin
    Tang, Xiumei
    Yang, Linhui
    Luo, Wenxin
    Li, Weimin
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (02)
  • [27] Prevalence, risk factors, and vaccine effectiveness of COVID-19 infection in thai children, adolescents, and young adults in the omicron era
    Chaiyakulsil, Chanapai
    Sritipsukho, Paskorn
    Satdhabudha, Araya
    Bunjoungmanee, Pornumpa
    Tangsathapornpong, Auchara
    Sinlapamongkolkul, Phakatip
    Sritipsukho, Naiyana
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [28] Revisiting a risk-benefit analysis of mRNA COVID-19 vaccines during the omicron era
    Lataster, Raphael
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2024, 193 (06) : 928 - 929
  • [29] Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study
    Ye, Li
    Yang, Ye
    Zhang, Xuewu
    Wang, Lu
    Zhu, Li
    Li, Xia
    Zhou, Yile
    Zheng, Xiaolong
    Zhou, Xinping
    Ren, Yanling
    Ma, Liya
    Xu, Gaixiang
    Yang, Chunmei
    Wang, Huafeng
    Zhou, De
    Yang, Min
    Ye, Xingnong
    Wei, Juying
    Yu, Wen-Juan
    Qian, Jiejing
    Lou, Yinjun
    Xie, Wanzhuo
    Huang, Jian
    Meng, Haitao
    Jin, Jie
    Tong, Hongyan
    BLOOD, 2023, 142
  • [30] Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis
    Degirmenci, Huseyin Berk
    Oh, Jinseo
    Bays, Alison M.
    Thomason, Jenna L.
    Liew, Jean W.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)